Evidence map›Paper›PMID 40637990›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2025

DCF-resistant ESCC redevelops drug sensitivity when combined with calcium channel blockers due to ER stress response.

Wenjie Liao, Satoru Matsuda, Tetsuya Takimoto, Kazumasa Fukuda, Masashi Takeuchi, Hirofumi Kawakubo, Hideyuki Saya, Yuko Kitagawa

Abstract read
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Next Generation Calcium Nanomaterials: Disrupting Tumor CaInternational journal of nanomedicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenjie LiaoDepartment of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Satoru MatsudaDepartment of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. s.matsuda.a8@keio.jp.ORCID 0000-0001-8441-2755
Tetsuya TakimotoDivision of Gene Regulation, Oncology Innovation Center, Fujita Health University, Nagoya, Japan.
Kazumasa FukudaDepartment of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Masashi TakeuchiDepartment of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Hirofumi KawakuboDepartment of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Hideyuki SayaDivision of Gene Regulation, Oncology Innovation Center, Fujita Health University, Nagoya, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.

Funding

JSPS KAKENHI JP 23K08221
6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma(ESCC) often develops resistance to standard chemotherapy regimens of docetaxel/cisplatin/5-fluorouracil(DCF) therapy. Strategies to overcome chemoresistance remain a significant clinical challenge.

methodsDCF-resistant ESCC cell lines were established in the beginning through long-term exposure to chemotherapeutic agents. Gene expression profiles were analyzed via RNA sequencing, and functional assays were conducted to evaluate the impact of various calcium channel blockers(CCBs) on cell viability.

resultsTranscriptomic analysis revealed enrichment of endoplasmic reticulum(ER) stress pathways in DCF-resistant ESCC cells. Among CCBs tested, combined therapy DCF with CCBs restored chemosensitivity.

conclusionDCF-resistant ESCC cells were resensitized with combined therapy with DCF and CCBs by enhacing ER stress response. This may provide a potential rationale for repurposing CCBs as adjuvant agents in chemotherapy of ESCC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCalcium Channel BlockersDrug Resistance, NeoplasmEndoplasmic Reticulum StressEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaCell Line, TumorCell SurvivalCisplatinDocetaxelFluorouracilHumansCalcium Channel BlockersCisplatinDocetaxelFluorouracilCalcium channel blockersDrug evaluationDrug resistanceEndoplasmic reticulum stressEsophageal squamous cell carcinoma

Identifiers

PMID40637990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.